{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for m root_references_citation in Reference Text / Citation (approximate match)
Status:
Possibly Marketed Outside US
Source:
NAXCEL Sterile Powder by Yancey, R.J. et al.
Source URL:
First approved in 1988
Source:
NADA140338
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Ceftiofur is an antibiotic of the cephalosporin type (third generation), licensed for use in veterinary medicine only. It was first described in 1987. It is marketed by pharmaceutical company Zoetis as Excenel, Naxcel, and Excede and is also the active ingredient in that company's Spectramast LC (lactating cow formulation) and Spectramast DC (dry cow formulation) product. Ceftiofur has worldwide approvals for respiratory disease in swine, ruminants (cattle, sheep and goats) and horses and has also been approved for foot rot and metritis infections in cattle. Ceftiofur has also been approved in various countries for early mortality infections in day-old chicks and turkey poults. Ceftiofur (NAXCEL) is indicated for treatment of bovine respiratory disease (shipping fever, pneumonia) associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. NAXCEL is also indicated for treatment of acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus.
Status:
Possibly Marketed Outside US
Source:
NDA022276
(1988)
Source URL:
First approved in 1988
Source:
NDA022276
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333E
(2011)
Source URL:
First approved in 1988
Source:
21 CFR 333A
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
ANDA216232
(1987)
Source URL:
First approved in 1987
Source:
ANDA216232
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
Rejuvesol
Source URL:
First approved in 1987
Source:
21 CFR 349
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
CTI-01 (ethyl pyruvate) is an investigational anti-inflammatory agent for the treatment of critical inflammatory conditions. CTI-01 was developed by Critical Therapeutics as a stable prodrug of pyruvate, a potent antioxidant, and a free radical scavenger. The drug showed an anti-inflammatory and tissue protection activity in animal models of pancreatitis, ischemia-reperfusion injury, sepsis, renal injury, and endotoxemia. CTI-01 was investigated in phase 2 clinical trials on patients undergoing cardiac surgery with cardiopulmonary bypass, but despite positive results in animal models, administration of EP does not appear to confer any benefit to cardiac surgical patients undergoing cardiopulmonary bypass. Besides clinical applications, ethyl pyruvate is long used as an additive to pharmaceutical preparations and foods, including candy, beverages, and baked goods. It is generally recognized as safe by the FDA.
Status:
Possibly Marketed Outside US
Source:
ANDA209351
(1984)
Source URL:
First approved in 1984
Source:
ANDA209351
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Possibly Marketed Outside US
Source:
NCT02418130: Phase 4 Interventional Completed Fatigue
(2014)
Source URL:
First approved in 1984
Source:
NDA019018
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Taurine is a semi-essential amino acid and is not incorporated into proteins. Taurine is considered conditionally essential because it cannot be synthesized by infants younger than 4-6 weeks, and it may not be adequately synthesized in patients receiving long-term parenteral nutrition and patients with short-term hypermetabolic conditions. In mammalian tissues, taurine is ubiquitous and is the most abundant free amino acid in the heart, retina, skeletal muscle, brain, and leukocytes. Taurin occurs naturally in fish and meat. The mean daily intake from omnivore diets was determined to be around 58 mg. Taurine is a component of energy drinks, with many contain 1000 mg per serving. In medicine, taurine supplementation demonstrated efficacy in relieving symptoms of heart failure, hepatitis, hypertension and psychotic disorder. Taurine exerts many physiological functions, including membrane stabilization, osmoregulation and cytoprotective effects, antioxidant and anti-inflammatory actions as well as modulation of intracellular calcium concentration and ion channel function. In addition taurine may control muscle metabolism and gene expression, through yet unclear mechanisms. The cellular and biochemical mechanisms mediating the actions of taurine are not fully known.
Status:
Possibly Marketed Outside US
First approved in 1982
Source:
NADA113645
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
p-Chlorocresol (p-chloro-m-cresol; PCMC; brand name: Preventol CMK) possesses disinfectant and antiseptic properties. Chlorocresol is used in various preparations for skin disinfection and wounds. It also used as a preservative in creams and other preparations for external use which contain water. For use as a disinfectant such as a hand wash, it is commonly dissolved in alcohol in combination with other phenols. It is a moderate allergen for sensitive skin. Chlorocresol produces potentially life-threatening effects which include dermatitis, which are responsible for the discontinuation of chlorocresol therapy. The symptomatic adverse reactions produced by chlorocresol are more or less tolerable and if they become severe, they can be treated symptomatically, these include hypersensitivity reactions, irritation of eyes.
Status:
Possibly Marketed Outside US
First approved in 1981
Source:
ANDA204937
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
There is no information related to the biological and pharmacological application of levulinic acid. But is known, that levulinic acid was recognized by the US Department of Energy as one of the top biobased platform chemicals of the future. It is a versatile building block with a clear value proposition in chemicals. Levulinic acid can successfully address many performance-related issues attributed to petroleum-based chemicals and materials.
Status:
Possibly Marketed Outside US
Source:
FERMODYLFERMO FIVE by All Natural Dynamics
(2018)
Source URL:
First approved in 1980
Source:
Donnatal by Advanz Pharma (US) Corp.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
FD&C Yellow No. 5 (Tartrazine, Colour Index No. 19140) is a color additive permitted in the United States for coloring foods (including dietary supplements), ingested and externally applied drugs, and cosmetics. It is a nitrous derivative and is known to cause allergic reactions such as asthma and urticaria, as well as having been the focus of studies on mutagenesis and carcinogenesis due to its transformation into aromatic amine sulfanilic acid after being metabolized by the gastrointestinal microflora.